Erratum: Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF (Gene Therapy) (2005) vol. 12 (452-460) 10.1038/sj.gt.3302421);Inhibiting estrogen responses in breast cancer cells using a fusion protein encoding estrogen receptor-α and the transcriptional repressor PLZF

Gene Therapy

Volumn 12, Issue 5, 2005, Pages 452-460

  Buluwela, L ^a   Pike, J ^a   Mazhar, D ^a   Kamalati, T ^a   Hart, S M ^a   Al Jehani, R ^a   Yahaya, H ^a   Patel, N ^a   Sarwarl, N ^a   Heathcote, D A ^a   Schwickerath, O ^a   Phoenix, F ^a   Hill, R ^a   Aboagye, E ^a   Shousha, S ^b   Waxman, J ^a   Lemoine, N R ^a   Zelent, A ^c   Coombes, R C ^a   Ali, Simak ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer; Estrogen receptor; Gene expression; PLZF

Indexed keywords

CATHEPSIN D; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HYBRID PROTEIN; PROGESTERONE RECEPTOR; PROMYELOCYTIC LEUKEMIA ZINC FINGER PROTEIN; PROTEIN PS2; REPRESSOR PROTEIN; TETRACYCLINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DRUG POTENCY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HORMONE INHIBITION; HORMONE RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING;

MINK CELL FOCUS-FORMING VIRUS;

EID: 20144364363     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302529     Document Type: Erratum

References (42)

1. Kelsey JL, Berkowitz GS. Breast cancer epidemiology. Cancer Res 1988; 48: 5615-5623.
2. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
3. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001; 7: 2620-2635.
4. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870.
5. Tsai Mi, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994; 63: 451-486.
6. Luger K et al. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997; 389: 251-260.
7. Cheung P, Allis CD, Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell 2000; 103: 263-271.
8. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
9. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352.
10. Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998; 67: 545-579.
11. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000; 14: 121-141.
12. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002; 108 465-474.
13. Chen H et al. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 1999; 98: 675-686.
14. Brehm A, Kouzarides T. Retinoblastoma protein meets chromatin. Trends Biochem Sci 1999; 24: 142-145.
15. Ng HH, Bird A. DNA methylation and chromatin modification. Curr Opin Genet Dev 1999; 9: 158-163.
16. Bird AP, Wolffe AP. Methylation-induced repression - belts, braces, and chromatin. Cell 1999; 99: 451-454.
17. O'Neill LP et al. A developmental switch in H4 acetylation upstream of Xist plays a role in X chromosome inactivation. EMBO J 1999; 18: 2897-2907.
18. Fuks F et al. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat Genet 2000; 24: 88-91.
19. Fuks F et al. Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J 2001; 20: 2536-2544.
20. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001; 20: 3139-3155.
21. Robertson KD et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25: 338-342.
22. Borrow J et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
23. Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 1998; 91: 3127-3133.
24. Chen Z et al. Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia. EMBO J 1993; 12: 1161-1167.
25. He LZ et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 1998; 18: 126-135.
26. Lin RJ et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811-814.
27. Grignani F et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-818.
28. Guidez F et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998; 91: 2634-2642.
29. David G et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene 1998; 16: 2549-2556.
30. Green S, Issemann I, Sheer E. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res 1988; 16: 369.
31. Tora L et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 1989; 59: 477-487.
32. Chen D, Pace PE, Coombes RC, Ali S. Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 1999; 19: 1002-1015.
33. Ali S et al. Production and characterization of monoclonal antibodies recognising defined regions of the human oestrogen receptor. Hybridoma 1993; 12: 391-405.
34. Reid A et al. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood 1995; 86: 4544-4552.
35. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986; 83: 2496-2500.
36. Horwitz KB, McGuire WL. Nuclear mechanisms of estrogen action. Effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem 1978; 253: 8185-8191.
37. Kastner P et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990; 9: 1603-1614.
38. Brown AM, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 1984; 81: 6344-6348.
39. Morisset M, Capony F, Rochefort H. The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun 1986; 138: 102-109.
40. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905-2919.
41. Shang Y et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843-852.
42. Metivier R et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003; 115: 751-763.